AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02751203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make Safe Happen App
Description: The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
Study NCT04483674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide
Description: Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL
Study NCT03707067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garments
Description: Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
Study NCT03707067 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham recovery drink
Description: Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving
Study NCT02440360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PSH
Description: Please see arm description.
Study NCT02440360 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Please see arm description.
Study NCT03642756 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: different intra-arterial catheter size
Description: in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
Study NCT03642756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: different intra-arterial catheter size
Description: in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
Study NCT01419951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic + Home Behavioral Intervention
Description: A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
Study NCT01419951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatrician Counseling
Description: A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
Study NCT01419951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Only Behavioral Intervention
Description: A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
Study NCT03218098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy via UVATS
Description: lobectomy with small skin access 4 cm
Study NCT03218098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy via UVATS
Description: lobectomy with small skin access 4 cm
Study NCT00986544 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: no drain
Description: drain positioned on the skin
Study NCT00986544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drain positioned
Description: drain positioned in the subhepatic space
Study NCT00986544 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: drain not positioned
Description: Drain positioned in the abdominal wall
Study NCT03896542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial video game.
Description: Stroke patient had played with commercial video game, along 12 sessions.
Study NCT03896542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rehabilitation video game
Description: Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
Study NCT01825057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: See One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
Study NCT01825057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
Study NCT01825057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians.
Study NCT03831061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Study NCT02187172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Study NCT02187172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Study NCT02187172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00547872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise testing - coronary angiography - revascularization
Description: Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
Study NCT01792921 — intervention group
Intervention type: BEHAVIORAL
Intervention: COG - FUN
Study NCT02177396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02177396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT02177396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02177396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03324906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
Study NCT03485248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
Study NCT03485248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of Beetroot Juice (nitrate free)
Study NCT01345136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, everolimus
Description: Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Study NCT00929877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KETOPROFEN(RP19583)
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Study NCT00929877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Study NCT03593850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music group
Description: The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
Study NCT03593850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Silence Group
Description: Audio file that contained no sounds.
Study NCT00003895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16 E7:12-20
Description: Given SC
Study NCT00003895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M)
Description: Given SC
Study NCT00003895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00415857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (PR1 Peptide)
Description: PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
Study NCT00415857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
Study NCT00415857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Continue receiving imatinib by mouth at the same dose received during the last 6 months.
Study NCT00415857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
Study NCT03357315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study NCT05138042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (frozen glove)
Description: In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes.
Study NCT01380730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01380730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (Diptheria, Tetanus, Pertussis) Vaccine
Description: Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib (Haemophilus influenza b) Vaccine
Description: Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
Study NCT02426021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202 Placebo
Description: Subcutaneous administration of MLN1202 placebo
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib (Haemophilus influenza b) Vaccine
Description: Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV (Inactivated Polio Vaccine) Vaccine
Description: Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV (Inactivated Polio Vaccine) Vaccine
Description: Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate Vaccine
Description: Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate Vaccine
Description: Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR (Measles, Mumps, and Rubella) Vaccine
Description: One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR (Measles, Mumps, and Rubella) Vaccine
Description: One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: One vaccination of Varicella vaccine was administered at 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: One vaccination of Varicella vaccine was administered at 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Virus
Description: One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
Study NCT00806195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Virus
Description: One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
Study NCT01767454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
Study NCT01767454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
Study NCT01767454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
Study NCT02751593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40mg/d for 4 days
Study NCT04223843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol
Description: Oral Inhalation
Study NCT04223843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Inhalation
Study NCT01186120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent
Description: drug-eluting stent
Study NCT01186120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: drug-eluting stent
Study NCT01978782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Study NCT01978782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Study NCT01978782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Study NCT01978782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Study NCT00105716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone behavioral education
Study NCT00105716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer behavioral education
Study NCT00006151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
Study NCT00006151 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
Study NCT00018655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation
Description: Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
Study NCT00018655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Treatment
Description: Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
Study NCT04624464 — intervention group
Intervention type: OTHER
Intervention: Rectal swabs - microbiological analysis
Description: Microbial analyses will be performed from the rectal swabs obtained.
Study NCT04624464 — intervention group
Intervention type: OTHER
Intervention: Examination of patient room
Description: Only performed for cohort 2
Study NCT03081442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
Study NCT03081442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine contraceptive device IUCD
Description: bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus .
Study NCT03081442 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine contraceptive device IUCD
Description: bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus .
Study NCT01077648 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab or Lapatinib
Description: Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
Study NCT03677258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen for injections 7%
Description: Injection of medical device
Study NCT03677258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid for injections 2%
Description: Injection of medical device